Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ovarian Cancer with TTF-1-positive Giant Pleural Dissemination.
Tsuchiya K, Suzuki R, Miyamoto R, Tsunoda T, Ito T, Mori R, Akashi T, Oyama Y, Ikeda M. Tsuchiya K, et al. Among authors: oyama y. Intern Med. 2024 Oct 18. doi: 10.2169/internalmedicine.4324-24. Online ahead of print. Intern Med. 2024. PMID: 39428530 Free article.
Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration.
Okawa M, Yamakuchi M, Bibek A, Takenouchi K, Maywar DN, Yamada S, Inoue K, Higurashi K, Nakazawa J, Kawahira M, Kodama T, Tanoue K, Oyama Y, Higashi S, Fujisaki C, Hashinokuchi H, Tabaru A, Kanda H, Tachioka S, Imoto Y, Hashiguchi T, Soga Y. Okawa M, et al. Among authors: oyama y. PLoS One. 2024 Dec 19;19(12):e0316035. doi: 10.1371/journal.pone.0316035. eCollection 2024. PLoS One. 2024. PMID: 39700124 Free PMC article.
The Vascular Endothelial Growth Factor-A121/Vascular Endothelial Growth Factor-A165 Ratio as a Predictor of the Therapeutic Response to Immune Checkpoint Inhibitors in Gastric Cancer.
Hamada Y, Tanoue K, Arigami T, Yamakuchi M, Okawa M, Matsushita D, Takenouchi K, Yamada S, Maywar DN, Nakayama C, Oyama Y, Higashi S, Fujisaki C, Hozaka Y, Kita Y, Hashiguchi T, Ohtsuka T. Hamada Y, et al. Among authors: oyama y. Cancers (Basel). 2024 Nov 26;16(23):3958. doi: 10.3390/cancers16233958. Cancers (Basel). 2024. PMID: 39682145 Free PMC article.
Combination Therapy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel for Metastatic Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Resistance and EGFR Mutations.
Kobayashi H, Otsuki A, Ikeda S, Nakashima K, Oyama Y. Kobayashi H, et al. Among authors: oyama y. Cureus. 2024 Aug 20;16(8):e67307. doi: 10.7759/cureus.67307. eCollection 2024 Aug. Cureus. 2024. PMID: 39165617 Free PMC article.
804 results